Ingenious friend
Invizyne Technologies (IZTC), a development-stage biomanufacturer, has filed to raise approximately $17 million through an initial public offering.
Invizyne said in an SEC filing that it is considering offering 4.3 million shares at a price of $4 per share. Insurers would be given a 45-day option to purchase up to 645,000 additional shares to cover any over-allotments.
Public Ventures, a subsidiary of Invizyne’s majority shareholder, MDB, is serving as underwriter. Invizyne intends to list its shares on the Nasdaq under the symbol IZTC.
Last week, biotech Kyverna Therapeutics (KYTX) went public via an IPO that raised $319 million.
Read more about biotech IPOs
Telomir Pharmaceuticals shares tumble 29% after $7 million IPO
Moderna-backed Metagenomi sees shares tumble 31% after $94 million IPO
Kyverna Therapeutics Shares Rise 59% After $319 Million IPO